Articles in press and Articles in process
Brief Report P.1-4
Patient perspectives on switching from intravenous to subcutaneous infliximab and vedolizumab in inflammatory bowel disease: Results from a cross-sectional survey.
Author(s): Oldenburg L, Wijnands AM, Oldenburg B
Review Article P.1-5
Evaluation methods and polymers used in gastroretentive dosage forms: A recent update.
Author(s): Anjana MN*, A Pasupathi
Editorial P.1-2
Editorial Note on the Plasma-Proteome Gastro-Esophageal Cancers for Biomarkers
Author(s): Jessy Siban
Editorial P.1-1
Editorial Note on Anti-Tumour Surveillance in Immunotherapy-Treated HCC
Author(s): Jessy Siban
PDF